Dongfang Biology: Intends to terminate the research and development project, and the remaining funds will be used for shareholder approval.

Dongfang Bio announced that it plans to terminate the "Technology R&D Center Construction Project" and permanently supplement the remaining funds raised and interest to the working capital for daily operations. The project was planned to invest 82.572 million yuan, with 49.4616 million yuan invested as of December 23, and 42.318 million yuan unused. The reason for termination is due to the impact of public health events. The company has already invested its own funds in research and development equipment and building construction, and currently does not require further large investments in equipment. This matter does not constitute a related party transaction and still requires approval by the shareholders' meeting, with no objection from the sponsor institution.